Health & Food
Towards Global Equity in Early Alzheimer’s Detection
EARDREAM – Accelerating early detection of Alzheimer’s disease for everyone, anywhere.
How can we detect Alzheimer’s disease before the first symptoms arise, while assuring access to diagnosis to anyone, anywhere?
Alzheimer’s disease is a devastating disease, that to date, has no cure after onset. Nearly 35 Million individuals worldwide suffer the consequences of the disease alongside their family members. This number is expected to double every 20 years reaching 70 Million in 2040, of which 70% will be from low and middle income countries.
We are EARDREAM, a start-up that develops early detection biomarkers of Alzheimer’s disease and other neurological disorders — that is, before first behavioural symptoms are evident — based on a wearable device that could be accessed and utilised anywhere in the world.
Globally most Alzheimer’s cases remain undiagnosed (75% of people living with Alzheimer’s), particularly in rural or low-income regions. With EARDREAM, we aim at detecting Alzheimer’s disease as early as possible with approaches that are low-cost and can be deployed everywhere in the world benefiting all countries in the world equally.
This is an immense initiative that could revolutionise how we diagnose Alzheimer’s disease. Life expectancy drastically increased in the last few decades, and with that, the need to maintain a healthy and independent life well into advanced old age. Dementia-related disorders such as Alzheimer’s will affect many of us as we grow older. The time to enable early diagnoses and interventions is now, and with that hopefully delay and prevent the onset of Alzheimer’s across the globe.
Simon graduated from ETH Zurich as a mechanical engineer, focusing on bringing medical products to life. With a family case of Alzheimer's, he has a strong thrive to change the way this disease is detected and pave the path toward new interventions. Let's get in touch!